Journal article · 2026 · Open access
Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases
Clinical Pharmacology & Therapeutics, 119(4), 1005–1015 · Published 20 January 2026 · DOI 10.1002/cpt.70183
In brief
“Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases” is a 2026 journal article by Chiara Zecchin and 6 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 7 citations as of 17 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 7
- Most cited in
- 2026 (7)
- Field-weighted impact
- 13.82
- References
- 32
- Authors
- 7
Abstract
IL-5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL-5 activity, is commonly used to evaluate the efficacy of anti-IL-5 biologic therapies. Model-informed drug development (MIDD) and quantitative decision making (QDM) were used to shorten the clinical development of depemokimab (an ultra-long-acting anti-IL-5 biologic). A Bayesian nonlinear mixed effects dose-time response model predicted the depemokimab dose in severe asthma achieving comparable BEC reductions to those observed in mepolizumab (an approved anti-IL-5 biologic) Phase III MUSCA and MENSA trials. Prespecified QDM go/no-go criteria were applied to assess success probability. Phase IIb efficacy-based trial simulations were conducted using negative binomial distribution to simulate individual annualized exacerbation rate. A depemokimab PK/PD (BEC) model predicted Phase III trial doses in CRSwNP/EGPA/HES. Single depemokimab doses were well-described by the Bayesian model; a single depemokimab dose ≥ 60 mg had probability ≥ 80% of exceeding Minimum (78%; MUSCA) and ≥ 10% probability of exceeding Target (84%; MENSA) values for trough BEC reduction from baseline vs. placebo. Clinical trial simulations demonstrated < 3% probability of more precise estimation of the Phase III dosing regimen with a conventional efficacy-based dose-ranging study. Depemokimab 100 mg for severe asthma/CRSwNP and 200 mg for EGPA/HES, administered subcutaneously every 26 weeks, were selected for Phase III trials. MIDD and QDM shortened the depemokimab development program by 2-3 years, emphasizing the potential of this approach for progressing new therapies from Phase I directly to Phase III.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zecchin, C., Schalkwijk, S. J., Pouliquen, I. J., Berges, A., Bird, N., Follows, R., & Austin, D. J. (2026). Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases. Clinical Pharmacology & Therapeutics, 119(4), 1005–1015. https://doi.org/10.1002/cpt.70183
MLA 9
Zecchin, Chiara, et al. “Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases.” Clinical Pharmacology & Therapeutics, vol. 119, no. 4, 2026, pp. 1005–1015. https://doi.org/10.1002/cpt.70183.
Chicago
Zecchin, Chiara, Stein J. Schalkwijk, Isabelle J. Pouliquen, Aliénor Berges, Nicholas Bird, Richard Follows, and Daren J. Austin. 2026. “Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases.” Clinical Pharmacology & Therapeutics 119 (4): 1005–1015. https://doi.org/10.1002/cpt.70183.
Harvard
Zecchin, C. et al. (2026) ‘Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases’, Clinical Pharmacology & Therapeutics, 119(4), pp. 1005–1015. doi:10.1002/cpt.70183.
IEEE
C. Zecchin et al., “Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases,” Clinical Pharmacology & Therapeutics, vol. 119, no. 4, pp. 1005–1015, 2026, doi: 10.1002/cpt.70183.
BibTeX
@article{zecchin2026straight,
title = {{Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases}},
author = {Zecchin, Chiara and Schalkwijk, Stein J. and Pouliquen, Isabelle J. and Berges, Aliénor and Bird, Nicholas and Follows, Richard and Austin, Daren J.},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2026},
volume = {119},
number = {4},
pages = {1005--1015},
doi = {10.1002/cpt.70183},
url = {https://doi.org/10.1002/cpt.70183}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- depemokimab
- IL-5
- model-informed drug development
- quantitative decision making
- severe asthma
- chronic rhinosinusitis with nasal polyps
- eosinophilic granulomatosis with polyangiitis
- hypereosinophilic syndrome
Work with this paper
Most-cited papers in Mathematics
- Random ForestsLeo Breiman · Machine Learning · 2001 · 142,830 citations
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingYoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 113,923 citations
- Fitting Linear Mixed-Effects Models Using lme4Douglas M. Bates, Martin Maechler, Benjamin M. Bolker and 1 more · Journal of Statistical Software · 2015 · 100,328 citations
- The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Reuben M. Baron, David A. Kenny · Journal of Personality and Social Psychology · 1986 · 95,866 citations
- Using multivariate statisticsBarbara Gerson Tabachnick, Linda S. Fidell · 1983 · 79,867 citations
Questions about this paper
How do I cite this paper in APA style?
Zecchin, C., Schalkwijk, S. J., Pouliquen, I. J., Berges, A., Bird, N., Follows, R., & Austin, D. J. (2026). Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases. Clinical Pharmacology & Therapeutics, 119(4), 1005–1015. https://doi.org/10.1002/cpt.70183
How many times has this paper been cited?
7 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Chiara Zecchin, Stein J. Schalkwijk, Isabelle J. Pouliquen, Aliénor Berges, Nicholas Bird, Richard Follows, Daren J. Austin.
What is the DOI of this paper?
10.1002/cpt.70183, permanently at https://doi.org/10.1002/cpt.70183. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.